Rankings / Hormones & Endocrine
Minoxidil (topical + oral low-dose)
Hormones & Endocrine · Potassium channel opener / vasodilator
Also known as: Rogaine ·Loniten
Tier A+
Bottom line
Read Off Label grades Minoxidil (topical + oral low-dose) as A+ (8.4/10) based on strong evidence, strong benefit magnitude, and a low-risk safety profile.
Low-dose oral minoxidil has exploded in dermatology practice since 2018 for patients who can't tolerate topical (scalp irritation) or want easier adherence.
Studied, labeled, or reported-use context: Topical: 1 mL 5% solution or foam 1-2x/day; oral: 0. — OTC (topical); Rx; not individualized guidance.
Citation correction in progress
2 PubMed links were found to be unrelated to this entry and removed from public output. The remaining sources are shown below, but this row's claims and score still need a full source-by-source revalidation.
What the evidence says
Low-dose oral minoxidil has exploded in dermatology practice since 2018 for patients who can't tolerate topical (scalp irritation) or want easier adherence. NYT 2022 coverage drove huge public interest. Women typically use 0.625-2.5 mg/day; men 1.25-5 mg/day. Low-dose oral protocols often include blood-pressure monitoring; hypotension, edema, tachycardia, and rare pericardial effects are part of the reported safety context, with event rates varying by study and dose.
Mechanism
ATP-sensitive potassium channel opener; originally oral antihypertensive (Loniten) with hair-growth side effect discovered; prolongs anagen (growth phase); topical 2-5% is OTC standard; low-dose oral (0.25-5 mg) is a resurgent off-label regimen
Studied, labeled, or reported dose & route
Topical: 1 mL 5% solution or foam 1-2x/day; oral: 0.25-5 mg/day
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Minoxidil (topical + oral low-dose)'s effects?
- Read Off Label rates the evidence for Minoxidil (topical + oral low-dose) as Strong and the benefit magnitude as strong, producing an overall grade of A+ (8.4/10). Low-dose oral minoxidil has exploded in dermatology practice since 2018 for patients who can't tolerate topical (scalp irritation) or want easier adherence.
- What safety findings are reported for Minoxidil (topical + oral low-dose)?
- Minoxidil (topical + oral low-dose) has a low risk profile in the database. Low (topical: scalp irritation, unwanted facial hair, post-application shedding 4-8 weeks in; oral: fluid retention, ankle edema, hypertrichosis, rare pericardial effusion at higher doses) Legal status: OTC (topical); Rx (oral).
- What doses or routes are reported for Minoxidil (topical + oral low-dose)?
- Topical: 1 mL 5% solution or foam 1-2x/day; oral: 0.25-5 mg/day This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Minoxidil (topical + oral low-dose) work?
- ATP-sensitive potassium channel opener; originally oral antihypertensive (Loniten) with hair-growth side effect discovered; prolongs anagen (growth phase); topical 2-5% is OTC standard; low-dose oral (0.25-5 mg) is a resurgent off-label regimen
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.